Table 2.

NLR values across MBC patient subgroups.

N = 263		NLR		P*
		Median	Interquartile interval (Q1–Q3)
Performance status	ECOG 0–1	2.16	1.59–3.40	0.008
	ECOG 2–3	2.93	2.07–3.79
Histology	Ductal	2.32	1.68–3.50	0.86
	Lobular	2.13	1.70–3.42
Metastases at diagnosis	M0	2.15	1.57–3.40	0.08
	M1	2.50	1.81–3.71
Estrogen receptora	ER negative	2.75	2.03–4.08	0.02
	ER positive	2.16	1.61–3.33
Progesterone receptor	PR negative	2.41	1.71–3.50	0.70
	PR positive	2.29	1.71–3.62
HER2	HER2 negative	2.23	1.65–3.40
	HER2 positive	2.58	1.81–4.00
Tumour subtype	HR+ HER2−	2.13	1.60–3.15	0.09
	HR+ HR+	2.35	1.75–3.51
	HR+ HR-	3.23	2.16–4.17
	TNBC	2.41	1.92–4.00
Metastasis location	Bone/soft parts (SP)	2.13	1.59–3.00	0.04
	Visceral	2.36	1.57–3.58
	Visceral + Bone/SP	2.46	1.83–5.10
Number of metastasis locations	<2 locations	2.16	1.59–3.30	0.06
	> = 2 locations	2.50	1.81–4.25
Visceral disease	Yes	2.44	1.75–4.18	0.03
	No	2.13	1.59–3.00
CNS metastasis	No CNS disease	2.25	1.65–3.42	0.006
	CNS disease	3.14	2.50–6.21
Visceral crisis	No	2.24	1.64–3.33	<0.001
	Yes	4.83	2.08–8.86
Recurrence during adjuvant treatment	No	2.24	1.64–3.70	0.45
	Yes	2.12	1.55–3.00

*Mann-Whitney U-text or Kruskal-Wallis test.